Kirkland Represents KKR-backed Slayback Pharma in Sale to Azurity Pharmaceuticals

Kirkland & Ellis advised Slayback Pharma LLC on its sale to Azurity Pharmaceuticals Inc, which was announced September 27. The sellers included investment firm KKR and private equity firm Everstone Capital. Slayback is now a wholly-owned subsidiary of privately-held pharmaceutical company Azurity. Slayback focuses on complex generic and specialty pharmaceutical products.

Read the transaction press release

The Kirkland team was led by corporate partners Neil Vohra, Andrew Arons and Jennifer Perkins and associates Lisa Gunter, Sophie Frishberg and Gino Jacobazzi; antitrust & competition partners Rich Cunningham and Samantha Morelli; tax partners Mike Beinus and Vivek Ratnam; debt finance partners Paul Rezvani and associates Ashley Martin and Negin Fatahi; and technology & IP transactions partners Daniel Lewis and Amber Harezlak.